ArticlebioRxiv : the preprint server for biology2026
Targeting WNK1 Releases Differentiation Block in Acute Myeloid Leukemia.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Impaired differentiation is a hallmark of Acute Myeloid Leukemia (AML). Current differentiation therapies benefit only a small subset of AML patients, leaving a substantial gap in care for other subtypes. Identifying novel molecular drivers of maturation arrest is critical to expand differentiation induction to a broader range of AML patients. This study addresses this unmet clinical need, by identifying With-no-Lysine(K) kinase 1 (WNK1) as a novel regulator of AML differentiation arrest. We show that WNK1 expression and activity are elevated in AML patients. WNK1 inhibition induced differentiation accompanied by decreased growth and survival of AML cell lines and patient cells. It also inhibited self-renewal of AML patient cells in vitro and elicited significant anti-tumor activity in vivo in mouse models. Mechanistically, WNK1 inhibition derepressed the MEK-ERK-C/EBPβ signaling axis and increased the expression of myeloid differentiation genes. Our findings reveal a novel role of WNK1 in promoting AML through differentiation arrest, posing WNK1 inhibition as a potential approach for AML differentiation therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.